• Health Care M&A Deals, June 4, 2021

    The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry. The largest deal of the week... Read More »
  • WELL Health Buys MyHealth Partners

    It’s been a busy year for WELL Health Technologies Corp. (TSX.V: WELL). In early February, the company announced the acquisition of CRH Medical Corporation (NYSE: CRHM), which provides physicians with innovative services and products for the treatment of gastrointestinal diseases, for $292.7 million. Following that, in March the company... Read More »
  • Convey Health Announces its Going Public

    Healthcare technology firm Convey Holding Parent, Inc. announced a plan to raise $200 million through its upcoming IPO. The offering will consist of 13.3 million shares at an expected price range between $14 and $16 per share. In 2020, the company generated $288 million in consolidated revenue, a 28% increase over the previous year. Convey... Read More »
  • National Health Investors Grabs Brookhaven Hospital

    The healthcare REIT National Health Investors, Inc. (NYSE: NHI) is adding a behavioral health hospital to its portfolio. NHI is buying Brookhaven Hospital, a 64-bed specialty behavioral health hospital in Tulsa, Oklahoma, that specializes in treating patients that have suffered a traumatic brain injury. The deal is valued at $42.3 million; $40.3... Read More »
  • One Medical Buys Iora Health

    The primary care clinic operator One Medical (NASDAQ: ONEM) has expanded its network size with the acquisition of Boston, Massachusetts-based Iora Health. Under the terms of the agreement, Iora Health shareholders will receive 56.1 million shares of One Medical stock valued at the company’s closing price of $35.59 on June 4, 2021, or... Read More »
Trulieve Cannabis Merges With Harvest Health

Trulieve Cannabis Merges With Harvest Health

The medical marijuana market just got its biggest merger. Trulieve Cannabis Corp. (OTC: TCNNF), a vertically integrated “seed-to-sale” company, announced last week the acquisition of Harvest Health & Recreation Inc. for $2.1 billion. Harvest Health is a vertically integrated medical cannabis company and multi-state operator. The company also operates retail locations.  Trulieve will acquire all Harvest Shares, with each Harvest Shareholder receiving 0.1170 of a Trulieve Share for each Harvest Share, implying a price per Harvest Share of $4.79, a 34% premium to the May 7, 2021 closing price. Harvest Health generated $231.6 million in revenue in 2020 and... Read More »
Pfizer Acquires Amplyx Pharmaceuticals

Pfizer Acquires Amplyx Pharmaceuticals

After getting its Covid-19 vaccine to market in record time, Pfizer Inc. (NYSE: PFE) is back on the acquisition trail. The pharmaceutical giant has purchased Amplyx Pharmaceuticals, Inc. for an undisclosed sum. Amplyx Pharmaceuticals is a privately-held company dedicated to the development of therapies for debilitating and life-threatening diseases that affect people with compromised immune systems. Amplyx’s lead compound, Fosmanogepix (APX001), is a novel investigational asset under development for the treatment of invasive fungal infections.  In addition to Fosmanogepix, with this acquisition, Pfizer has secured ownership of Amplyx’s early-stage pipeline that includes potential antiviral... Read More »
Procaps Group Merges with Union Acquisition

Procaps Group Merges with Union Acquisition

If you were looking for another SPAC deal this week, say no more. Procaps Group announced a reverse merger with Union Acquisition Corp. II (NASDAQ: LATN). Founded in 1977, Procaps is a leading integrated international healthcare and pharmaceutical company with a successful history of growth and diversification. Procaps is the largest pharmaceutical integral CDMO in Latin America, and its proprietary portfolio of branded Rx and OTC products and services is sold, distributed, or provided to over 50 markets. It has six state-of-the-art manufacturing facilities in Latin America, including the first FDA-approved pharmaceutical plant in South America for selling Rx products into the United... Read More »
Jazz Pharmaceuticals Buys GW Pharmaceuticals

Jazz Pharmaceuticals Buys GW Pharmaceuticals

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is back with a new acquisition. The Ireland-based pharmaceutical company has announced the purchase of GW Pharmaceuticals plc (OTC: GWPRF) for $7.2 billion, or $220 per American Depositary Share in the form of $200 in cash and $20 in Jazz Pharmaceuticals ordinary shares. The price represents a premium of approximately 50% over GW’s closing stock price on February 2, 2021, of $146.25 and 60% over GW’s 30-day volume-weighted average price of $137.17. GW Pharmaceuticals is a global pharmaceutical company that discovers, develops, manufactures and commercializes novel, regulatory approved therapeutics from its proprietary cannabinoid product... Read More »
Servier Builds Oncology Portfolio With New Deal

Servier Builds Oncology Portfolio With New Deal

The France-based pharmaceutical company Servier is back with a new deal, adding Agios Pharmaceuticals, Inc.‘s (NASDAQ: AGIO) oncology portfolio for $1.8 billion upfront in cash. The portfolio consists of Agios’ commercial, clinical and research-stage oncology product line, which includes Tibsovo, a treatment for adults with IDH1-mutant relapsed or refractory acute myeloid leukemia, and additional oncology pipeline and clinical programs. The deal also includes Agios’ co-commercialization responsibilities for Bristol Myers Squibb’s (NYSE: BMY) IDHIFA and certain clinical development activities within the IDHIFA development program.  In addition to the upfront payment, Servier will pay Agios... Read More »
Servier Builds Oncology Portfolio With New Deal

Boston Scientific Divests BTG Specialty Pharmaceuticals Business

In November 2018, Boston Scientific Corporation (NYSE: BSX) purchased BTG plc for $4.8 billion, according to search results in our Healthcare Deal Database. BTG develops and commercializes products used in minimally-invasive procedures targeting cancer and vascular diseases. However, the company also had an acute care pharmaceutical division, which based on recent deal activity, it seemed the medical device giant wasn’t too interested in holding onto the non-medical device portions of BTG. In the fourth quarter of 2019, Boston Scientific sold the pharmaceutical licensing royalties unit of BTG, and last week, the company announced the second divestment. Boston Scientific is selling... Read More »